Dr. Tuszynski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 W Arbor Dr
San Diego, CA 92103Phone+1 800-926-8273
Education & Training
University of California (San Diego) Medical CenterResidency, Ph.D., Neurosciences, 1988 - 1991- University of California (San Diego) Medical CenterResidency, Neurology, 1987 - 1988
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1984 - 1987
University of Minnesota Medical SchoolClass of 1983
Certifications & Licensure
NY State Medical License 1984 - Present
CA State Medical License 1986 - 2025- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Gene Therapy for Alzheimer's Disease Clinical Trial
- A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment Start of enrollment: 2022 Feb 07
Roles: Principal Investigator, Contact, Sponsor-Investigator
Publications & Presentations
PubMed
- 20 citationsRhesus macaque versus rat divergence in the corticospinal projectome.Eleni Sinopoulou, Ephron S Rosenzweig, James M Conner, Daniel Gibbs, Chase A Weinholtz
Neuron. 2022-09-21 - 430 citationsSpontaneous corticospinal axonal plasticity and functional recovery after adult central nervous system injury.Norbert Weidner, Arvin Ner, Nima Salimi, Mark H. Tuszynski
Proceedings of the National Academy of Sciences of the United States of America. 2001-03-13 - 706 citationsA phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseMark H. Tuszynski, Leon J. Thal, Mary Pay, David P. Salmon, Hoi Sang U
Nature Medicine. 2005-04-24
Press Mentions
Stem Cell Grafts and Rehabilitation Combined Boost Spinal Cord Injury ResultsOctober 28th, 2022- The Best Countries Around the World for Medical ProgressJune 29th, 2021
- ClearPoint Neuro: A Biotech Portfolio PlayApril 5th, 2021
- Join now to see all
Grant Support
- Contusive Spinal Cord Injury Model DevelopmentVeterans Affairs2012
- Gene Therapy For Alzheimer'S DiseaseNational Institute On Aging2010–2012
- Plasticity And Regeneration In The Primate Spinal CordNational Institute Of Neurological Disorders And Stroke2001–2012
- Gene Therapy For Treatment Of Spinal Cord InjuryNational Center For Research Resources2005–2011
- Gene Therapy For Alzheimers DiseaseNational Center For Research Resources2003–2011
- Neurobiological Aspects Of AgingNational Institute On Aging2005–2009
- Combinatorial Approaches To SCINational Institute Of Neurological Disorders And Stroke2004–2008
- Gene Therapy For Treatment Of Spinal InjuryNational Center For Research Resources2003–2004
- Netrins And Gene Therapy After Spinal Cord InjuryNational Institute Of Neurological Disorders And Stroke2001–2003
- Gene Therapy In PrimatesNational Institute On Aging2002
- Estrogen Mediated Neuronal Plasticity In The BrainNational Institute On Aging1999–2002
- Safety &Feasibility Of Direct In Vivo NGF Gene Transfer To Primate BrainNational Center For Research Resources1999–2002
- Diffusion NGF &Biological Response From Basal Forebrain Cholinergic NeuronsNational Center For Research Resources1999–2002
- Gene Therapy In PrimatesNational Institute On Aging1997–2001
- Ex Vivo Schwann Cell Gene Therapy For CNS RepairNational Institute Of Neurological Disorders And Stroke1998–2000
- Gene Therapy In CNS Trauma (NGF04)National Center For Research Resources1998
- Gene Therapy In CNS TraumaNational Center For Research Resources1997
- Genetically Modified Cells In PrimatesNational Institute On Aging1994
- Cholinergic Neuronal Regeneration In The CNSNational Institute Of Neurological Disorders And Stroke1987
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
